Haemonetics relocates HQ to downtown Boston

Haemonetics (NYSE:HAE) said yesterday it plans to relocate to downtown Boston from its previous home in Braintree, Mass.

The move will position the blood-focused device developer in a 62,000 square-foot of space at 125 Summer Street, the company said, and will allow it to sell its 17-acre Braintree campus.

“We’re excited to welcome Haemonetics to 125 Summer Street as we continue to create a destination for innovative companies. We look forward to continuing our partnership with them to create an inspiring workspace for their employees,” Oxford Properties senior leasing manager Matthew Polhemus said in a prepared statement.

Haemonetics touted that the move will allow it to “right-size” its footprint, having inked a multi-year lease through to 2032 for the new location. The new headquarters will be located across four floors in a 495,000 square foot building in Boston.

“Haemonetics’ move to Boston will position our teams to work in close proximity to the city’s world-class healthcare, technology and higher education communities and its thriving culture of innovation. As a company driving accelerated growth, this move will provide a dynamic space to engage our employees as we advance our ways of working,” prez & CEO Chris Simon said in a press release.

In September, the French government reportedly decided on a precautionary suspension of the use of a blood collection device made by Haemonetics – used in half of all donations there – after receiving numerous reports of problems with the devices.

The post Haemonetics relocates HQ to downtown Boston appeared first on MassDevice.

from MassDevice https://ift.tt/2S7EHfD